Advancing immunotherapy with the development of a novel STING mRNA analog

Strong synergistic activity of an EZH1/2 dual inhibitor, HM97662, in combination with standard chemotherapy in preclinical models of advanced solid tumors

Preclinical efficacy of a selective, orally bioavailable HER2 small molecule inhibitor targeting HER2 alterations and Enhertu-resistant cancers

HM100760, a potent and selective MAT2A inhibitor, demonstrates a synergistic anticancer effect when combined with a PRMT5 inhibitor in MTAP-deleted cancer

NGS-based molecular profiling reveals remarkable anticancer synergy of EZH1/2 dual inhibitor HM97662 with standard-of-care therapy on small cell lung cancer

Development of Selective HER2 Covalent Inhibitors with Brain Penetration for Effective Treatment of CNS Metastases

Transcriptional modulations of tumor microenvironment by BH3120, a PD-L1x4-1BB bispecific antibody, in patient-derived organotypic tumor spheroids (PDOTS) model

Employing synthetic mRNA therapeutic platform to restore p53 function to suppress growth of p53 mutant cancer

BH3120, a PD-L1x4-1BB bispecific antibody, exhibits favorable safety profiles in distinct in vivo and ex vivo liver toxicity evaluations

Hanmi’s p53 mRNA and abraxane synergistically promote tumor control in PTX-prefered cancer through p53 stabilization

Discovery of a novel SOS1-KRASmulti inhibitor, HM101207, demonstrates a broad-spectrum antitumor activity across KRAS-MAPK mutant cancers